Compare POM & HYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POM | HYFT |
|---|---|---|
| Founded | 2015 | 1983 |
| Country | China | United States |
| Employees | N/A | 102 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.2M | 53.3M |
| IPO Year | N/A | N/A |
| Metric | POM | HYFT |
|---|---|---|
| Price | $0.31 | $1.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 629.7K | 175.8K |
| Earning Date | 05-03-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.99 |
| 52 Week High | $6.43 | $3.00 |
| Indicator | POM | HYFT |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 39.53 |
| Support Level | $0.28 | $1.02 |
| Resistance Level | $0.43 | $1.31 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 68.97 | 26.56 |
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.